Second Transplant for Relapsed AML, Learning from Defeat
In patients with acute myeloid leukemia (AML), the development of recurrent disease after allogeneic hematopoietic stem cell transplantation (HSCT) is associated with a dismal prognosis. Commonly used strategies such as the withdrawal of immunosuppressive agents, the use of targeted molecules or chemotherapy, donor lymphocyte infusion (DLI), or a second transplant (HSCT2) can benefit only the selected few. Therefore, it is critical to identify subsets of patients who derive the most benefit from a specific salvage approach.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Usama Gergis, Dolores Grosso Tags: The Bottom Line Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Biology | Chemotherapy | Hematology | Learning | Leukemia | Stem Cell Therapy | Stem Cells | Transplants | Universities & Medical Training